Modification at C6 of the Terminal Galactosyl Residues of Cobra Venom Factor Abolishes Anti-alpha-Gal Antibody Immunoreactivity without Affecting Functional Activity

By Gowda D.C.  

Biochemical and Biophysical Research Communications, Vol. 245, Iss. 1, 1998-04 ,pp. : 28-32

Elsevier

Access to resources Recommend Favorite

Molecular mimicry in the recognition of glycosphingolipids by Galα3Galβ4GlcNAcβ-binding Clostridium difficile toxin A, human natural anti α-galactosyl IgG and the monoclonal antibody Gal-13: characterization of a binding-active human glycosphingolipid, non-identical with the animal receptor

By Teneberg Susann   Lönnroth Ivar  

Glycobiology, Vol. 6, Iss. 6, 1996-09 ,pp. : 599-609

Oxford University Press

Access to resources Recommend Favorite

Xenotransplantation: in vitro analysis of synthetic α -galactosyl inhibitors of human anti-Gal α 1 → 3Gal IgM and IgG antibodies

By Rieben Robert   V.Bovin Nicolai  

Glycobiology, Vol. 10, Iss. 2, 2000-02 ,pp. : 141-148

Oxford University Press

Access to resources Recommend Favorite

Synthesis and characterization of a novel glycopolymer with protective activity toward human anti-α-Gal antibodies

By Vetere A.   Donati I.   Campa C.   Semeraro S.   Gamini A.   Paoletti S.  

Glycobiology, Vol. 12, Iss. 4, 2002-04 ,pp. : 283-290

Oxford University Press

Access to resources Recommend Favorite

Specificity of xenoreactive anti-Galα1–3Gal IgM for α-galactosyl ligands

By Parker William   Lateef Jarama   Everett Mary Lou   Platt Jeffrey L.  

Glycobiology, Vol. 6, Iss. 5, 1996-07 ,pp. : 499-506

Oxford University Press

Access to resources Recommend Favorite